Brazil trials are important because after filling quickly, the interim analysis at half way point is very probably going to give Janet and Brazil a very low and acceptable p value. This is because a) leronlimab is efficacious and safe and b) we learned from CD12 about how to design a successful trial with a great product, the Primary Endpoint will be carefully selected, and will be met. The negative is the time element, more waiting. My hope is that this combination
a) desperation (we are already there) and b) "Compassionate Use" programs, in many nations, will domino into much demand and revenue very soon, like now.